Pharmacokinetics of amphotericin B after accidental overdose in an adult critically ill patient treated with plasmapheresis: a case report and review of literature
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20240386Keywords:
Amphotericin B, Medication error, Pharmacokinetics, Critical careAbstract
Amphotericin B is a broad-spectrum antifungal agent that is used in the treatment of systemic fungal infections. We describe the case of a 62-year-old female patient with recent aneurysmal subarachnoid hemorrhage who was treated for suspected ventriculitis and a fungal coinfection. Instead of liposomal amphotericin B (L-AmB), 465 mg (5 mg/kg) amphotericin B deoxycholate (DOC) was inadvertently administered, leading to refractory shock with multiple organ failure and requiring mechanical ventilation. Since an overdose of amphotericin B can lead to fatal consequences and has a half-life of 15 days, plasmapheresis was started. The serum concentration decreased from 1.32 µg/mL to 0.62 µg/mL before plasmapheresis, demonstrating a mean half-life of 49 hours. After two plasmapheresis sessions, the serum concentration further dropped to 0.26 µg/mL, demonstrating a mean half-life of 17 hours. In contrast, the third plasmapheresis session had no effect on serum concentration. The patient made a full recovery, potentially facilitated by enhanced amphotericin B elimination through plasmapheresis. Positive outcomes were previously reported in two adult patients treated with plasmapheresis. However, other reports without plasmapheresis described fatal outcomes in adult patients, albeit with a twofold overdose compared to the two patients successfully treated with plasmapheresis. Moreover, plasmapheresis itself carries risks such as hypocalcemia, metabolic alkalosis, and coagulation deficits. Consequently, the role of plasmapheresis in amphotericin B overdose is still debated.
References
Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 2013;73(9):919-34.
Laniado-Laborín R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol 2009;26(4):223-7.
Mohr JF, Hall AC, Ericsson CD, Ostrosky-Zeichner L. Fatal amphotericin B overdose due to administration of nonlipid formulation instead of lipid formulation. Pharmacotherapy. 2005;25(3):426-8.
Burke D, Lal R, Finkel KW, Samuels J, Foringer JR. Acute amphotericin B overdose. Ann Pharmacother 2006;40(12):2254-9.
Wang GS, Banerji S, Roussil TK, Heard KJ. Survival after amphotericin B overdose treated with plasmapheresis. Ann Pharmacother. 2013;47(2):e9.
Monroig-Bosque PDC, Balk J, Segura F, Salazar E, Leveque CM, Ipe TS. The utility of therapeutic plasma exchange for amphotericin B overdose. Transfus Apher Sci. 2018;57(6):756-8.
Atkinson Jr AJ, Bennett JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother. 1978;13(2):271-6.
Hoeprich PD. Elimination half-life of amphotericin B. J Infect. 1990;20(2):173-5.
Koren G, Lau A, Kenyon CF, Kroppert D, Klein J. Clinical course, and pharmacokinetics following a massive overdose of amphotericin B in a neonate. J Toxicol Clin Toxicol. 1990;28(3):371-8.
Brent J, Hunt M, Kulig K, Rumack B. Amphotericin B overdoses in infants: is there a role for exchange transfusion? Vet Hum Toxicol. 1990;32(2):124-5.
Perlman JM, Acarregui M, Gard JW. Fatal overdose of amphotericin B in two preterm infants. Dev Pharmacol Ther. 1991;17(3-4):187-90.
Cleary JD, Hayman J, Sherwood J, Lasala GP, Piazza-Hepp T. Amphotericin B overdose in pediatric patients with associated cardiac arrest. Ann Pharmacother. 1993;27(6):715-9.
Groeneveld S, Verweij PE, Hek LV, Bökkerink JPM, Warris A. Amphotericin B-deoxycholate overdose due to administration error in pediatric patients. Med Mycol. 2008;46(2):185-7.
Lew SQ. Amphotericin B removal by plasma exchange. J Clin Pharm Ther. 2009;34(1):115-7.
